The Onshoring Advantage: Seven Forces Reshaping Global Biologics Manufacturing

The global landscape for biologics manufacturing is shifting rapidly. Once defined by cost-driven offshore strategies, the industry now faces mounting pressures from policy changes, trade volatility, and national security concerns. Legislation like the BIOSECURE Act, potential tariffs on foreign-made drugs, and the lingering effects of COVID-19 have exposed vulnerabilities in global supply chains. Investors, boards, and regulators are demanding greater transparency, resilience, and speed to market — prompting biopharma companies to rethink where and how they manufacture critical therapies.

In this executive white paper, Avid Bioservices outlines seven disruptive forces reshaping biologics manufacturing and driving a steady shift toward U.S.-based production. Drawing on real-world technology transfers and industry insights, the paper highlights how forward-looking drug developers are proactively securing domestic capacity, mitigating risk, and future-proofing their pipelines. Whether you're preparing for pivotal trials or scaling commercial supply, this resource offers strategic guidance to help you navigate the evolving manufacturing landscape.